Table 1Paraparetic patients

Reference:Population Group
Paraparesis (walking or not)
Patient Characteristics
Tumour type -Cord or cauda
Time from diagnosis to treatment (days or hours)Outcomes: Number that remained ambulantChange in Functional status
Leviov, M., et al., 199370 patients
Ambulant (n=24);
Paraparetic/Non-ambulant (n=27)
Breast; Prostate; Lung; Lymphoma; Unknown (not broken down by ambulatory status)
MSCC or cauda (numbers not reported separately)
Not reportedFrom Ambulant Group: Remained ambulant (n=16, 66%);

From Paraparetic Group: Became ambulant (n=8, 30%)
Not reported
Bach, F., et al., 1990398 patients
Paraparetic (n=165)
Breast; Prostate; Lung; Kidney; (not broken down by ambulatory status)
- cord only
Mean duration from first symptom to diagnosis: 58 days (average 30 days, range 0–420 days)

Mean duration from first visit to doctor and diagnosis of SCC: 23 days (average 4 days, range 0–360 days)
No deficit (n=5);
Mild deficit (n=30);
Remained paraparetic (n=98);
Became paraplegic (n=32)
Not reported as a functional status
Gilbert, R.W., Kim, J-H., Posner, J.B., 1978235 patients
Paraparetic (n=116, 49%)
Breast; Prostate; Lung; Kidney; Lymphoma/myeloma; melanoma; GI; others (not broken down by ambulatory status)
- cord only
Not reportedBecame ambulant (n=52, 45%)Duration of improvement: 75% of living patients who improved from treatment remained ambulatory at 6 months;
50% at one year
Solberg, A. Bremnes, R.M., 199986 patients
Mild/moderate motor function deficit (n=29);
Severe motor function deficit (n=46)
Breast; Prostate; Lung; Kidney (breakdown of numbers not reported)
- cord only
Median duration from first symptom to first doctor contact:
4 day (range 0–30)

Median duration to hospital admission and treatment start:
6 days (range 0–158)
8 days (range 0–208)
From Mild/moderate Group:
No deficit (n=5);
Mild/moderate deficit (n=17);
Severe deficit (n=3);
Paraplegic (n=2)

From Severe Group:
No deficit (n=2);
Mild/moderate deficit (n=14);
Severe deficit (n=24);
Paraplegic (n=5)
A significantly larger part of ambulant patients (35%) achieved treatment response 2 or 3, compared to 22% of non-ambulant patients;
82% experienced significant pain reduction; pain relief was obtained in all patients with full motor function recovery

From: Chapter 5, Choice of Imaging

Cover of Metastatic Spinal Cord Compression
Metastatic Spinal Cord Compression: Diagnosis and Management of Patients at Risk of or with Metastatic Spinal Cord Compression.
NICE Clinical Guidelines, No. 75.
National Collaborating Centre for Cancer (UK).
Copyright © 2008, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.